

Attorney Docket No. (P3250) 6675.142US1
Response to Office Action Dated April 11, 2005

Serial No. 09/359,260

Remarks

I. Introduction

By the present Amendment, claims 128-130 and 133 have been cancelled, and claims 76, 82-89, 92-95, 131, 132, and 134 amended. Claims 135-138 are newly presented for consideration. Accordingly, claims 76, 82-95, 131, 132, and 134-138 are now pending in the application.

II. Interview Summary

Applicants and their representatives thank the Examiner for the courtesy and cooperation extended during the interview conducted on June 20, 2005 at the U.S. Patent and Trademark Office. Present at the interview were Examiner Eric S. DeJong, Ph.D., Primary Examiner John S. Brusca, Ph.D., Leonid D. Thenor, and Belinda Lew, Ph.D.

During the interview, Applicants provided a PowerPoint presentation as an overview of the invention and methodology. Claims 76, 82-95, and 128-134 were discussed with respect to all rejections of record. The claims were also discussed with respect to Ostrem et al. Examiner Brusca discussed the manner in which a whole molecule parameter could be interpreted as a sequence-specific parameter if additional amino acids were added or removed from a particular peptide. The term "relationship" was indicated as being broad relative to the disclosure. It was also indicated that the claims did not specify that the second test peptide library could contain members that were not present in the first peptide library. It was indicated that Ostrem identified peptides of different lengths as well as a second library that contained members from the first library. It was also indicated that the specification did not appear to support the term "compound isomer", as recited in claim 129.

Interview Summary Okay
EDJ 10/11/2005